A Phase 2a/b Randomized Double-blind Placebo-controlled Parallel Group

Recruiting

99 years or below

All

1 Location

Brief description of study

A study to investigate efficacy and safety of OG-6219 BID in 3 dose levels compared with Placebo in participants aged 18 to 49 with moderate to severe endometriosis-related pain

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 12 Apr 2023. Study ID: 853419

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase 2a/b Randomized Double-blind Placebo-controlled Parallel Group Multicenter Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels in Women 18 to 49 Years of Age with Moderate to Severe Endometriosis-related Pain

Brief description of study

Eligibility of study

Find a site

Interested in the study